2m 2m 2m 2m 2m 2m 2m
SPERO THERAPETCS (SPRO)
NASDAQ
$2.88+$0.08 (+3.00%)
Price as of Jun 03, 2026 7:57 PM EDT- $163.9MMarket Cap
- 7.20%1-Year Change
- BiotechnologyIndustry
SPERO THERAPETCS (SPRO)
$2.88+$0.08 (+3.00%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 66.8M +39.24% | 48.0M -53.77% | 103.8M +93.95% | 53.5M +193.10% | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 66.8M +39.24% | 48.0M -53.77% | 103.8M +93.95% | 53.5M +193.10% | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -38.5M -60.24% | -96.8M +88.10% | -51.4M +8.08% | -47.6M -26.24% | |
Depreciation and Amortization Expense | 0 -100.00% | 2,000 -99.46% | 367,000 -57.77% | 869,000 +34.52% | |
Total Operating Expenses | 60.5M -50.15% | 121.3M +47.43% | 82.3M -14.01% | 95.7M -9.90% | |
Operating Profit | 6.3M +108.61% | -73.4M -441.52% | 21.5M +150.91% | -42.2M -52.03% | |
Interest Income | 2.5M -46.95% | 4.7M +20.27% | 3.9M +255.97% | 1.1M +219.65% | |
Interest Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 2.5M -46.95% | 4.7M +20.27% | 3.9M +255.97% | 1.1M +219.65% | |
Total Nonoperating Income and Expense | 2.5M -47.47% | 4.8M +22.23% | 3.9M +193.01% | -4.2M +136.30% | |
Income before Taxes | 8.8M +112.88% | -68.6M -369.90% | 25.4M +160.20% | -42.2M -52.03% | |
Income Taxes | 261,000 N/A | 0 -100.00% | 2.6M N/A | 0 N/A | |
Extraordinary Items | 587,000 N/A | 0 -100.00% | 5.3M +735.59% | 635,000 N/A | |
Net Income | 8.6M +112.50% | -68.6M -400.65% | 22.8M +149.13% | -46.4M -48.29% | |
Net Income from Continuing Operations Applicable to Common | 8.6M +112.50% | -68.6M -400.65% | 22.8M +149.13% | -46.4M -48.29% | |
Basic EPS and Net Income | 0.15 +111.81% | -1.27 -395.35% | 0.43 +134.96% | -1.23 -57.73% | |
Diluted EPS and Net Income | 0.15 +111.81% | -1.27 -395.35% | 0.43 +134.96% | -1.23 -57.73% | |
Basic Weighted Average Shares | 56.0M +3.67% | 54.0M +2.53% | 52.7M +40.22% | 37.6M +21.65% | |
Diluted Weighted Average Shares | 59.0M +9.26% | 54.0M +1.98% | 53.0M +40.98% | 37.6M +21.65% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 40.3M -23.87% | 52.9M -30.71% | 76.3M -30.04% | 109.1M -3.09% | |
Short-Term Investments | N/A N/A | N/A N/A | N/A N/A | 0 -100.00% | |
Cash and Cash Equivalents and Short-Term Investments | 40.3M -23.87% | 52.9M -30.71% | 76.3M -30.04% | 109.1M -25.47% | |
Total Current Assets | 67.3M -37.28% | 107.3M -18.24% | 131.2M +15.53% | 113.6M -28.06% | |
Accumulated Depreciation | N/A N/A | 3.6M +0.06% | 3.6M +11.25% | 3.3M +12.92% | |
Property and Plant and Equipment and Net | N/A N/A | 0 -100.00% | 2,000 -99.46% | 368,000 -64.13% | |
Total Long-Term Assets | 153,000 0.00% | 153,000 -64.83% | 435,000 -92.42% | 5.7M +1.70% | |
Total Assets | 68.9M -37.65% | 110.5M -39.39% | 182.4M +46.14% | 124.8M -27.05% | |
Income Taxes Payable | 383,000 +120.11% | 174,000 -55.04% | 387,000 N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 8.9M -81.93% | 49.1M +32.09% | 37.2M +71.62% | 21.6M +15.96% | |
Total Long-Term Debt | 91,000 N/A | 0 -100.00% | 87,000 -9.37% | 96,000 -30.43% | |
Total Long-Term Liabilities | 939,000 -93.64% | 14.8M -78.64% | 69.2M +154.95% | 27.1M +74.30% | |
Total Liabilities | 9.9M -84.64% | 64.4M -14.67% | 75.5M +54.49% | 48.9M -40.97% | |
Retained Earnings | -451.1M -1.86% | -459.6M +17.53% | -391.1M -5.51% | -413.9M +12.63% | |
Total Stockholders Equity | 59.0M +27.96% | 46.1M -56.85% | 106.9M +40.77% | 75.9M -13.99% | |
Total Shares Outstanding | 56.4M +3.34% | 54.6M +3.01% | 53.0M +1.04% | 52.5M +61.93% | |
Cash Flow | |||||
Cash from Operating Activities | -12.6M -46.15% | -23.4M -28.95% | -33.0M +326.79% | -7.7M -87.99% | |
Capital Expenditures | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Investing Activities | N/A N/A | N/A N/A | 0 -100.00% | 33.8M +340.65% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | N/A N/A | 0 -100.00% | 221,000 +100.75% | -29.6M -135.16% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | 9.45% +106.18% | -152.91% -838.75% | 20.70% +126.25% | -78.86% -83.63% | |
Return on Assets | 9.55% +120.41% | -46.81% -415.28% | 14.85% +147.32% | -31.37% -43.28% | |
Return on Equity | 16.31% +118.19% | -89.62% -459.22% | 24.95% +144.13% | -56.53% -30.62% | |
Revenue Growth | 39.24% +172.97% | -53.77% -157.23% | 93.95% -51.35% | 193.10% +101.84% | |
Current Ratio | 7.59 +247.10% | 2.19 -38.10% | 3.53 -32.68% | 5.25 -37.96% | |
Cash Ratio | 4.54 +321.31% | 1.08 -47.55% | 2.05 -59.23% | 5.04 -16.42% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow